Niche Immune Mod AyuVis focuses on a novel platform that modulates macrophages to balance immune responses, positioning the company to address inflammatory and infectious diseases with a potentially differentiated immunomodulatory approach.

Orphan Drug Advantage Lead candidate has Orphan Drug and Rare Pediatric Disease designation from the FDA for preventing bronchopulmonary dysplasia in at-risk preterm infants, creating a clear regulatory and market-entry pathway with potential incentives.

Early Stage Partnerships Historical collaboration with UNT Health Science Center and participation in incubator programs suggest readiness for academic and translational partnerships, which can be leveraged for co-development, access to facilities, and non-dilutive funding channels.

Funding Momentum Secured NIH SBIR grants and a $2.1 million grant for first-in-human trials indicate validated early-stage funding momentum, signaling potential for continued non-dilutive and early-stage financing as a sales/BD talking point.

Small Team, Big Potential With a lean team and a revenue range of 1–10 million, AyuVis presents an opportunity for strategic partnerships with larger pharma to accelerate development, expand indications, and provide access to manufacturing and distribution capabilities.